As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...
The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 ...
This oncogenic fusion drives aberrant tyrosine kinase activity ... T-Cell Lymphomas T-cell lymphomas exhibit diverse genetic aberrations, with ALK rearrangements defining anaplastic large cell ...
Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.
Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from ...
9. Revolutionary Energy Technology Breakthrough in fusion power or similar technology promises virtually unlimited cheap clean energy within a decade. Global growth prospects soar while inflation ...
Major Finding: Multiple oncogenic fusion kinases converge on GUK1 to augment GTP synthesis and promote lung cancer growth. Concept: ALK phosphorylates the GDP-synthesizing enzyme GUK1 at tyrosine 74 ...
1Department of Pediatric Hematology and Oncology, Justus-Liebig University, Giessen, Germany. 2Department of Pathology, Boston Children´s Hospital, Boston, Massachusetts. 3Department of Pediatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback